TransMedics Group, Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable…
Medical - Devices
US, Andover [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 4.59 | 9.72 | 9.30 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -48.61 | 9.87 | 19.20 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 15.82 | 4.87 | 4.20 | |
| Cash | -11.61 | 10.69 | 12.09 | |
| Capex | -5.26 | -1.35 | -1.28 | |
| Free Cash Flow | -41.55 | -1.45 | -1.03 | |
| Revenue | 18.89 | 2.96 | 2.49 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 4.69 | 0.62 | 0.59 | |
| Operating Margin | 299.94 | 0.13 | 0.03 | |
| ROA | 195.15 | 0.02 | < 0.005 | |
| ROE | 160.33 | 0.08 | 0.03 | |
| ROIC | 334.51 | 0.02 | < 0.005 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of TMDX is permitted for members.
5
Growth
The "Growth Entry" for the Focus of TMDX is permitted for members.
6
Leverage & Liquidity